Methods for radiotherapy to trigger light activation drugs

Patent metadata

Field	Value
Publication number	US-11786595-B2
Application number	US-202117227753-A
Country	US
Kind code	B2
Filing date	Apr 12, 2021
Priority date	Oct 26, 2015
Publication date	Oct 17, 2023
Grant date	Oct 17, 2023

Abstract

A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

First claim

The invention claimed is:

1. A method for treating a subject with a disorder, comprising:
providing within the subject at least one photoactivatable drug for treatment of the subject;
applying initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating the at least one photoactivatable drug, wherein applying comprises applying the initiation energy through a low mass filter; and
from said CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

2. The method of claim 1 , wherein applying the initiation energy through a low mass filter comprises applying the initiation energy through a section of carbon-containing material which is between 1 cm and 20 cm thick.

3. The method of claim 1 , wherein applying the initiation energy through a low mass filter comprises applying the initiation energy through a section of carbon-containing material which is between 5 cm and 15 cm thick.

4. The method of claim 1 , wherein applying the initiation energy through a low mass filter comprises applying the initiation energy through a section of carbon-containing material which is between 7 cm and 12 cm thick.

5. The method of claim 1 , wherein applying the initiation energy through a low mass filter comprises applying the initiation energy through a section of carbon-containing material containing at least one of H, F, Si, N, P, and B.

6. The method of claim 1 , wherein applying the initiation energy through a low mass filter comprises applying the initiation energy through a section of carbon-containing material containing in a minority amount at least one of H, F, Si, N, P, and B.

7. A method for treating a subject with a disorder, comprising:
providing within the subject at least one photoactivatable drug for treatment of the subject;
applying initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating the at least one photoactivatable drug; and
from said CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder, wherein activating inside the subject the at least one photoactivatable drug comprises bonding the photoactivatable drug to a cellular structure.

8. The method of claim 7 , wherein the bonding comprises at least one of 1) bonding the photoactivatable drug to at least one of nuclear DNA, mRNA, rRNA, ribosome, mitochondrial DNA and 2) bonding the photoactivatable drug to lipid bilayers of a virus.

9. The method of claim 7 , wherein the bonding comprises bonding the photoactivatable drug to lipid bilayers of at least one virus selected from the group consisting of an ebola virus, an encephalitis virus, a West Nile virus, and an HIV virus.

10. A method for treating a subject with a disorder, comprising:
providing within the subject at least one photoactivatable drug for treatment of the subject;
applying initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating the at least one photoactivatable drug; and
from said CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder, wherein activating inside the subject the at least one photoactivatable drug comprises activating a psoralen.

11. The method of claim 10 , further comprising activating inside the subject the at least one photoactivatable drug comprises activating 8 MOP or AMT.

12. A method for treating a subject with a disorder, comprising:
providing within the subject at least one photoactivatable drug for treatment of the subject;
applying initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating the at least one photoactivatable drug; and
from said CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder, wherein activating inside the subject the at least one photoactivatable drug comprises activating an alkylating agent.

13. A method for treating a subject with a disorder, comprising:
providing within the subject at least one photoactivatable drug for treatment of the subject;
applying initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating the at least one photoactivatable drug; and
from said CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder, wherein activating inside the subject the at least one photoactivatable drug comprises activating 1,5-iodonophthylazide.

14. A method for treating a subject with a disorder, comprising:
providing within the subject at least one photoactivatable drug for treatment of the subject;
applying initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating the at least one photoactivatable drug; and
from said CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder, wherein activating inside the subject the at least one photoactivatable drug comprises activating a drug for treating a cell proliferation disorder.

15. A method for treating a subject with a disorder, comprising:
providing within the subject at least one photoactivatable drug for treatment of the subject;
applying initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating the at least one photoactivatable drug; and
from said CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder, wherein activating inside the subject the at least one photoactivatable drug comprises activating a drug for treating at least one of a virus or a bacterium.

16. The method of claim 1 , further comprising energy modulating the CR light with a fluorophore.

17. The method of claim 16 , further comprising
activating a biological response inside the subject.

18. The method of claim 1 , wherein applying initiation energy comprises applying a filtered set of x-rays to the subject having an energy of at least 0.5 MeV and less than 10 MeV.

19. The method of claim 1 , wherein applying initiation energy comprises applying a filtered set of x-rays to the subject having an energy of at least 1.0 MeV and less than 10 MeV.

20. The method of claim 1 , wherein applying initiation energy comprises applying a filtered set of x-rays to the subject having an energy of at least 1.5 MeV and less than 10 MeV.

21. The method of claim 1 , wherein applying initiation energy comprises applying a filtered set of x-rays to the subject having an energy of at least 1.0 MeV and less than 10 MeV.

22. A method for treating a subject with a disorder, comprising:
providing within the subject at least one photoactivatable drug for treatment of the subject;
applying initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating the at

Assignees

• Immunolight Llc
• Univ Duke

Inventors

• Oldham Mark
• Adamson Justus
• Dewhirst Mark W
• Yoon Paul
• Walder Harold
• Bourke Jr Frederic A
• Fathi Zakaryae
• Beyer Jr Wayne F

Classifications

• A61K41/0066 Primary

  Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins · CPC title

• A61K31/352

  condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K31/658)} · CPC title

• A61K31/403

  condensed with carbocyclic rings, e.g. carbazole · CPC title

• A61K31/409

  having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555) · CPC title

• A61K31/525

  Isoalloxazines, e.g. riboflavins, vitamin B2 · CPC title